Lineage Cell Therapeutics (LCTX) Return on Sales (2010 - 2026)

Lineage Cell Therapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 0.11% for Q1 2026.

• On a quarterly basis, Return on Sales fell 7.0% year-over-year to 0.11% in Q1 2026; TTM through Mar 2026 was 0.05%, a 3.0% decrease from a year earlier, with the FY2025 full-year figure at 0.04%, down 2.0% from the prior year.
• Return on Sales slipped to 0.11% in Q1 2026 per LCTX's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q3 2024 and bottomed at 0.11% in Q1 2026.
• The 5-year median for Return on Sales is 0.02% (2023), against an average of 0.04%.
• Across the five-year window, Return on Sales gained 8 bps in 2022 and slipped 7 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.03% in 2022, then soared by 32 bps to 0.02% in 2023, then soared by 50 bps to 0.01% in 2024, then increased by 22 bps to 0.01% in 2025, then slumped by 1172 bps to 0.11% in 2026.
• Per Business Quant, the three latest LCTX Return on Sales figures stand at 0.11% (Q1 2026), 0.01% (Q4 2025), and 0.05% (Q3 2025).